Posted by Michael Wonder on 02 Jun 2023
Kyverna Therapeutics granted FDA fast track designation for KYV-101 in lupus nephritis
1 June 2023 - KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy designed to deplete B cells, including auto-reactive B cells in autoimmune disease patients.
Kyverna Therapeutics today announced the US FDA has granted fast track designation for KYV-101 for the treatment of patients with refractory lupus nephritis.
